Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q92521
UPID:
PIGB_HUMAN
Alternative names:
GPI mannosyltransferase III; Phosphatidylinositol-glycan biosynthesis class B protein
Alternative UPACC:
Q92521; Q53FF9; Q8WVN7
Background:
GPI mannosyltransferase 3, also known as GPI mannosyltransferase III and Phosphatidylinositol-glycan biosynthesis class B protein, plays a crucial role in glycosylphosphatidylinositol-anchor biosynthesis. This enzyme is responsible for transferring the third alpha-1,2-mannose to Man2-GlcN-acyl-PI during GPI precursor assembly, a key step in the biosynthesis of GPI anchors that are essential for attaching certain proteins to cell membranes.
Therapeutic significance:
The protein is implicated in Developmental and Epileptic Encephalopathy 80 (DEE80), a severe neurological disorder characterized by early-onset refractory seizures, neurodevelopmental impairment, and a poor prognosis. Understanding the role of GPI mannosyltransferase 3 could open doors to potential therapeutic strategies for treating DEE80 and related conditions.